from Abbott Vascular and Micropor. N.J.C. reports institutional research grants from the Novo Nordisk Foundation.

References
1. Russo V, Wahbi K. Appropriate timing of electrophysiological study in Myotonic Dystrophy type 1: unsolved question. *Europace* 2022;24:1036.
2. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Backash IM et al 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. *Europace* 2022;24:71–64.
3. Lazaar A, Paris N, Ouakhnane Z, Radvanyi H, Junien C, Castet J et al Electrophysiological study with prophylactic pacing at surgery and survival in adults with myotonic dystrophy and conduction system disease. Relationships among electrophysiological findings and clinical status, heart function, and extent of DNA mutation in myotonic dystrophy. *Circulation* 1999;99:1041–6.
4. Wahbi K, Meune C, Pichard R, Bécane HM, Lazarus A, Laforté P et al Electrophysiological study with prophylactic pacing at surgery and survival in adults with myotonic dystrophy and conduction system disease. *JAMA* 2012;307:1292–301.
5. Wahbi K, Babuty D, Probst V, Wissocque L, Labombarda F, Pichard R et al Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. *Eur Heart J* 2017;38:751–8.
6. Joosten IBT, van Lohuizen R, van der Zwaluw N, van Engelen BGM et al Electrocardiographic predictors of infraclinical conduction disturbances in myotonic dystrophy type 1. *Europace* 2021;23:298–304.

Carsten W Israel1, Michael Glikson2,3, and Jens Cosedis Nielsen1

1Department of Cardiology, Bethel-Clinic, University of Westphalia, Biegele, Germany; *Jeselton Integrated Heart Center Shaare Zedek Medical Center and Hebrew University Faculty of Medicine, PO Box 3235, Jerusalem 91030, Israel; and 2Department of Clinical Medicine and Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark

*Corresponding author. Tel: +972 2 6555975; fax: +972 2 6555437. E-mail address: mglikson@szmc.org.il

https://doi.org/10.1093/europace/eua316
Published online 24 December 2021

**New-onset perioperative atrial fibrillation in cardiac surgery patients: transient trouble or persistent problem?**

New-onset atrial fibrillation (AF) is the most frequent postoperative complication occurring after cardiac surgery. Despite its high incidence, uncertainty remains regarding the long-term significance of postoperative atrial fibrillation (POAF). Clinicians struggle to identify which, if any, patients who develop POAF should receive lifelong oral anticoagulation to reduce their risk of stroke.

Bidar et al used implantable loop recorders (ILRs) to track early and late POAF occurrences in 79 cardiac surgery patients in the Netherlands. They defined ‘early POAF’ as AF occurring within 5 days after surgery and ‘late POAF’ as occurring after this period. Early POAF lasting at least 2 min was detected in 27 patients (95% confidence interval (CI): 24–46%). Among this group, 67% (95% CI: 46–83%) experienced late AF recurrence over an average follow-up of 29 months (range: 4 days–53 months). These results are similar to those from a contemporary study by Abdelmoneim et al using ILR that detected AF recurrence in 71% (95% CI: 55–84%) of 42 American cardiac surgery patients with newly-onset AF over a mean follow-up of 1.7±1.2 years.

These studies both documented high AF recurrence rates in patients with POAF and call into question current practices in the long-term management of patients with POAF. It is known that longer durations of electrocardiogram (ECG) monitoring will capture more AF episodes and that longer AF episodes are associated with a higher risk of stroke. Two important questions however remain: how long should patients with POAF be monitored for AF recurrence and what duration of AF warfarin (AF war--) warrants lifelong anticoagulation? There are currently myriad ECG monitoring methods available, ranging from intermittent methods that patients can use at home (e.g. hand-held ECG), to traditional continuous ambulatory ECG monitors with durations ranging from 24 h to 14 days, to modern ILRs with upwards of 3 years of battery life. It is not practical and prohibitively expensive to monitor all cardiac surgery patients with ILRs, but shorter monitoring may underestimate AF recurrence.

Postoperative atrial fibrillation occurs in 25–40% of cardiac surgery patients and effective stroke prevention therapies are readily available: improving risk stratification for these patients should be a priority. Identifying the optimal monitoring strategy and the minimum AF burden associated with a stroke risk that justifies oral anticoagulation are central to such a strategy. Prospective, multicentre studies are needed to clarify the management of this population.

**Conflict of interest:** E.P.B.-C. reports grants from Bayer, Bristol Myers Squibb-Pfizer, and grants from Roche, outside the submitted work. W.F.M. reports speaking fees from Servier and Bayer, outside the submitted work.

References
1. Bidar E, Zeemering S, Gilbers M, Isaacs A, Verheule S, Zink MD et al Clinical and electrophysiological predictors of device-detected new-onset atrial fibrillation during 3 years after cardiac surgery. *Europace* 2021;23:1922–30.
2. Abdelmoneim SS, Rosenberg E, Meykler M, Patel B, Reddy B, Ho J et al The incidence and natural progression of new-onset postoperative atrial fibrillation. *JACC Clin Electrophysiol* 2021;7:1134–1144.
3. Kaur H, Belley-Côté EP, McIntyre WF. Is new-onset post-operative AF a first presentation of paroxysmal AF? The answer is still unclear. *JACC Clin Electrophysiol* 2021;7:1435–1436.
4. Chen LY, Zhang MK, Allen LA, Ezekowitz M, Furie KL, McCabe P et al. American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association. *Circulation* 2018;137:e623–44.
5. Khurshid S, Healey JS, McIntyre WF, Lubitz SA. Population-based screening for atrial fibrillation. *Circ Res* 2020;127:143–54.

Hargun Kaur1, Emilie P Belley-Côté2,3,4, and William F McIntyre2,3,4

1Faculty of Health Sciences, McMaster University, 1280 Main St W, Hamilton, ON L8S 4L8, Canada; 2Department of Health Research Methods, Evidence and Impact, McMaster University, 1280 Main St W, Hamilton, ON L8S 4L8, Canada; 3Population Health Research Institute, 237 Barton St E, DBVSPRI C3-13A, Hamilton, ON L8L 2X2, Canada and; and 4Division of Cardiology, Department of Medicine, McMaster University, 1280 Main St W, Hamilton, ON L8S 4L8, Canada

*Corresponding author. Tel: +1 905 521 2100, ext: 40414; fax: +1 905 297 3786. E-mail address: William.McIntyre@phri.ca

https://doi.org/10.1093/europace/eua317
Published online 24 December 2021

**New-onset perioperative atrial fibrillation in cardiac surgery patients: transient trouble or persistent problem?—Authors’ reply**

We are grateful for the opportunity to respond to the questions raised in Dr Kaur’s letter. Previously, our group showed that atrial fibrillation (AF) in the first days after cardiac surgery is associated with high AF recurrence rate during...
long-term continuous rhythm follow-up suggesting that postoperative AF (POAF) is not limited to the perioperative phase. Based on these findings, two relevant questions regarding the long-term management of patients with POAF arise.

Firstly, it remains unclear for how long patients with early-POAF (POAF during first 5 postoperative days) should be monitored for AF recurrences. We demonstrated that 67% of early-POAF patients also developed late POAF and that almost 80% of patients developed their first AF episode within the first postoperative month. Therefore, the first postoperative month is a crucial period for strict rhythm monitoring in patients undergoing cardiac surgery. In addition to clinically available Holter electrogram monitoring, photoplethysmography recording, or handheld devices are promising tools for this purpose.

Secondly, it is unclear what duration of AF warrants initiation of lifelong anticoagulation. New-onset POAF after coronary artery bypass grafting has been identified as an independent predictor of stroke, myocardial infarction, and death during prolonged period of follow-up, and subclinical AF has been detected in 30% of patients with cryptogenic stroke. On the other hand, a recent study reported no significant risk reduction for stroke or systemic embolism in patients screened with an implantable loop recorder (ILR) as compared to usual care. In this study, oral anticoagulant (OAC) was initiated in 29.7% of patients with ILR compared to 13.1% in the non-ILR group, suggesting that only clinically manifested AF, requires OAC. Accordingly, the ASSERT trial reported that only patients with longest episodes of subclinical AF (SCAF) (>24 h) had an increased risk of thromboembolic stroke as opposed to patients with shorter SCAF. Nevertheless, silent stroke was not considered in these studies and others have demonstrated SCAF as an independent predictor of silent ischaemic brain lesions in patients without clinical AF.

Notably, we also demonstrated that patients developing POAF had complex electrical conduction patterns during electrically induced AF. In addition, POAF patients had prolonged PR interval and enlarged right atrium, suggesting a more pronounced atrial structural remodelling as compared to patients without POAF, which may develop into a substrate for clinical AF. This is in line with previous studies demonstrating POAF as an independent predictor of clinical AF development.

In conclusion, continuous rhythm monitoring during the first postoperative month after cardiac surgery identifies many patients at risk of developing late POAF recurrences. However, the clinical impact of late POAF and subclinical AF in general population remains unclear. Circumstantial evidence suggests that longer episodes increase the risk of stroke, and POAF may also reflect early structural remodelling resulting in increased risk of AF development. Future studies should focus on the potential benefit of OAC in (silent) stroke prevention in subgroups of patients with late POAF and efforts should be undertaken to apply substrate modification and risk factor reduction in this potentially vulnerable population.

Conflict of interest: none declared.

References

1. Kaur HB-C, McIntyre WF. New-onset peri-operative atrial fibrillation in cardiac surgery patients: transient trouble or persistent problem? Europace 2022;24:1038.
2. Bidar E, Zeemering S, Gilbers M, Isaacs A, Verheule S, Zink MD et al Clinical and electrophysiological predictors of device-detected new-onset atrial fibrillation during 3 years after cardiac surgery. Europace 2021;23:1922–30.
3. Svendsen JH, Diederichsen SZ, Højberg S, Krieger DW, Graff C, Kronborg C et al Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet 2021;398:1507–16.
4. Van Gelder IC, Healey JS, Crijns H, Wang J, Hohnloser SH, Gold MR et al Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J 2017;38:1339–44.
5. Benezet-Mazuecos J, Rubio JM, Cortés M, Iglesias JA, Calle S, de la Vega JJ et al Silent ischaemic brain lesions related to atrial high rate episodes in patients with cardiac implantable electronic devices. Europace 2015;17:364–9.